News >

Researchers Continue to Explore Optimal Use of Radium-223

Published: Tuesday, Jun 30, 2015

Tanya B. Dorff, MD

Tanya B. Dorff, MD

Limited data exist regarding optimal patient selection and sequencing of radium-223 relative to other approved treatments for patients with metastatic castration-resistant prostate cancer (mCRPC).1 In a presentation given at the 2015 ASCO Annual Meeting, Tanya B. Dorff, MD, Keck School of Medicine of USC, discussed the available research on the radiopharmaceutical agent.

Patient Selection

Radium-223 was approved in 2013 for the treatment of patients with metastatic CRPC and bone metastases,1 based on data from the phase III ALSYMPCA trial in patients with metastatic CRPC who received radium-223.2

The ALSYMPCA trial randomized 928 men with bone pain from metastatic CRPC who had either progressed on docetaxel or who were not candidates for docetaxel, to radium-223 or placebo (each given monthly for 6 total doses) plus standard care.2

Data reported at an interim analysis showed a median overall survival of 14 months versus 11.2 months with radium-223 versus placebo, respectively (HR = 0.70; P = .00185). The time to the first skeletal-related event was a median of 15.6 months in the radium-223 arm compared with 9.8 months with placebo (HR = 0.658; P = .00037).

There was no clear distinction regarding radium-223 benefit according to the extent of disease (as defined by the number of bone lesions). Subgroup analyses did not provide definitive information on which patients may benefit, as the numbers of patients were small.2 There was no difference in median time to PSA progression between the radium-223 and placebo arms.2

These results confirm the need for further studies to define patient groups most likely to benefit from radium-223 treatment. “I would contend that there is really no clinical marker as of now that can help us to say, ‘This is a patient who shouldn’t get radium or who wouldn’t benefit.’ There is limited utility in these subgroup analyses,” concluded Dorff.


Determining the treatment sequence of radium-223 relative to other therapies is challenging for clinicians. Because of the potential for additive myelosuppression from radiopharmaceuticals and cytotoxic chemotherapy, most studies have focused on the timing of radium-223 either before or after docetaxel-based chemotherapy.1 Retrospective analysis from ALSYMPCA found somewhat higher rates of hematologic toxicity and packed red blood cell transfusions in patients receiving radium-223 who previously received docetaxel compared with those who did not.3

“But you will see that the grade 3 and 4 numbers remain relatively low, and I would argue that there’s nothing here that tells me it’s not safe to use this. So you can really choose to use this before or after docetaxel,” said Dorff.

“Similarly, when you look at transfusions, there are more transfusions, but you will see that they are for both the radium and the placebo group in the docetaxel pretreated cohort, suggesting that maybe some of this is related to disease burden…but again, I don’t think this is prohibitive in terms of choosing to use this before or after docetaxel,” she continued.

In addition, subgroup analysis of ALSYMPCA revealed that, although symptomatic skeletal events were not delayed in docetaxel-naïve patients, there was a substantial delay in these events in patients who were pretreated with docetaxel. “This gets back to that concept that maybe earlier on, patients are just not at as much risk, so they will stand perhaps greater benefit to using radium-223 later, after docetaxel,” commented Dorff.

The number of included patients was small; however, cautious interpretation suggests that docetaxel-pretreated patients may represent a group in which bone-targeting therapy may produce a greater effect.1

“Speaking to that, they found that there were actually about 5 fewer hospital days per patient per year in the docetaxel-naïve cohort that was treated with radium compared to placebo, and about 8 fewer hospital days per patient per year for docetaxel-pretreated patients treated with radium-223, suggesting that there is really a palliative benefit here,” Dorff noted.

“In patients who have received radium-223, they may require less palliative external beam radiotherapy down the road…if you are faced with a patient who is in pain, it might be reasonable to try the radium-223 first, and then if they are not experiencing pain palliation add the external beam radiation, but some patients may end up not needing it.”

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication